Malaria Tablets Africa: Malarone vs Doxycycline vs Lariam Compared
Choosing the Right Malaria Prophylaxis for Africa
Malaria prophylaxis is one of the most important and most frequently misunderstood elements of African safari health preparation.
The three main antimalarial medications recommended for travelers to sub-Saharan Africa are atovaquone-proguanil (Malarone), doxycycline, and mefloquine (Lariam).
All three provide effective protection against malaria when taken correctly. They differ significantly in their dosing schedules, side-effect profiles, cost, and practical suitability for different types of travelers.
Understanding these differences before your travel clinic appointment allows you to have a more informed conversation with your prescribing physician.
It also helps you make a choice that is well-matched to your specific travel plans, budget, and medical history.
The choice of antimalarial is a medical decision that must be made in consultation with a qualified physician who knows your complete medical history, current medications, and specific travel itinerary.
This guide provides general information about the three main options to help you understand what to ask about at your clinic appointment. It is not a substitute for professional medical advice.
You should not choose or obtain antimalarials without a prescription and physician consultation. Malaria is a potentially fatal disease. The correct prevention strategy for your specific situation requires professional assessment.
Atovaquone-Proguanil (Malarone)
The Most Commonly Prescribed Option for East Africa
Dosing and Effectiveness
Atovaquone-proguanil (Malarone and generic equivalents) is the most commonly prescribed antimalarial for travelers to East and Southern Africa. It is widely considered the most convenient option for short-to-medium-duration trips.
The dosing schedule is one tablet daily, starting one to two days before entering the malarial area and continuing for seven days after leaving. This is the shortest post-travel course of any of the three main options.
This short post-travel window makes Malarone particularly practical for travelers who find remembering medication for several weeks after returning home difficult to sustain.
It also significantly reduces the total number of tablets required for a two-week safari compared to the four-week post-travel course that doxycycline requires.
The effectiveness of atovaquone-proguanil against the Plasmodium falciparum malaria strains that cause most serious disease in sub-Saharan Africa is high.
Efficacy studies consistently show protection rates above 95 percent in controlled trials. The medication targets two different stages of the malaria parasite’s life cycle. Atovaquone targets the liver stage and proguanil targets the blood stage.
This means it both prevents infection from establishing after a mosquito bite and suppresses any breakthrough infection before it can cause symptoms. This dual mechanism is part of why Malarone’s post-travel course can be shorter than doxycycline’s.
The liver-stage activity means fewer parasites can persist in the liver and cause delayed-onset disease after the course ends.
Side Effects and Cost
Atovaquone-proguanil has a relatively favorable side-effect profile compared to both doxycycline and mefloquine. Most travelers experience no significant adverse effects during a standard course.
The most commonly reported side effects are gastrointestinal—nausea, abdominal discomfort, and occasional vomiting. These can be reduced by taking the tablet with food and at the same time each day. Headache is occasionally reported. Serious adverse reactions are rare.
The medication is not recommended during pregnancy, for individuals with severe renal impairment, or for infants under 11 kilograms. There are no significant neuropsychiatric side effects, which distinguishes it favorably from mefloquine.
There is also no photosensitivity, which distinguishes it favorably from doxycycline in Africa’s high UV environment.
The primary disadvantage of atovaquone-proguanil is cost. Brand-name Malarone is significantly more expensive than doxycycline. Generic equivalents have reduced prices substantially in most markets, but the per-tablet cost remains higher than doxycycline for equivalent-duration trips.
For a four-week trip, the cost difference between Malarone and doxycycline can be significant depending on the market and whether generics are available on prescription.
Travelers planning extended stays of more than four to six weeks often find that doxycycline’s lower per-tablet cost makes it substantially more economical.
This cost consideration is one of the factors that physicians weigh alongside side-effect profiles and medical history when recommending between the two options.
Doxycycline
The Budget-Friendly Daily Option
How Doxycycline Works and Its Schedule
Doxycycline is a broad-spectrum antibiotic with antimalarial activity. It provides effective protection against malaria when taken daily throughout the travel period. Unlike atovaquone-proguanil, doxycycline does not have liver-stage activity against the malaria parasite.
This means a longer post-travel course is required to ensure that any parasites that established themselves in the liver during the travel period are cleared before they can mature into blood-stage disease.
This post-travel course is four weeks — significantly longer than Malarone’s seven-day period. Compliance throughout this period is essential for the medication to provide its full protective effect.
The medication must begin two days before entering the malarial area, the same lead time as Malarone.
Doxycycline’s primary advantage over atovaquone-proguanil is cost. It is substantially cheaper per tablet in all markets, making it the preferred option for travelers on extended African trips.
It is also more widely available in generic form globally, making it accessible for travelers who need to obtain medication outside their home country. Additional antibiotic benefits—activity against certain other travel-associated infections, including some sexually transmitted infections and some respiratory infections—are occasionally cited as secondary advantages. However, antimalarial courses should not serve as primary treatment for other conditions.
Photosensitivity and Other Side Effects
Doxycycline’s most clinically relevant side effect for African safari travelers is photosensitivity. An increased susceptibility to sunburn that occurs in some users. This can be severe in high UV environments.
Africa’s high-altitude savanna and equatorial environments have intense ultraviolet radiation. Travelers taking doxycycline who develop photosensitivity can experience burns from relatively brief sun exposure.
Strategies to manage photosensitivity include high-SPF sunscreen applied consistently to all exposed skin and protective clothing.
And avoiding the midday sun when UV intensity peaks. Not all doxycycline users develop significant photosensitivity, and the reaction varies widely between individuals.
It is one of the factors that physicians discuss when comparing doxycycline to atovaquone-proguanil for specific travelers.
Gastrointestinal side effects — nausea, esophageal irritation, and in some cases exacerbation of reflux — are the most commonly reported adverse effects.
They can be significantly reduced by taking the tablet with a large glass of water and remaining upright for at least 30 minutes after taking it.
Doxycycline is not recommended during pregnancy, for children under eight years, or for those with significant sun sensitivity or a history of esophageal problems.
Doxycycline absorption reduces when taken with dairy. The tablet should be taken separately from dairy-containing meals rather than with a glass of milk. Oral contraceptives are sometimes cited as a potential interaction.
The clinical evidence for significant reduction in contraceptive efficacy is weak. Travelers using hormonal contraception should discuss this with their prescribing physician.
Mefloquine (Lariam)
Weekly Dosing and Important Considerations
Mefloquine Dosing and Effectiveness
Mefloquine (Lariam and generic equivalents) is the only weekly-dosed antimalarial recommended for African travel. This gives it a practical advantage for travelers who find daily tablet routines difficult to maintain consistently.
The dosing schedule requires beginning the medication at least two to three weeks — ideally five weeks — before departure. This allows time to confirm tolerance before leaving home, where any adverse effects can be managed with medical support nearby.
Mefloquine continues weekly throughout the travel period and for four weeks after leaving the malarial area.
The extended pre-travel course is both the medication’s key practical advantage and its key practical challenge for travelers planning trips within a shorter lead time.
Mefloquine has a long half-life — it persists in the body for weeks after the last dose. This is why the short-course pre-travel dosing achieves therapeutic blood levels and why the four-week post-travel course maintains protection while residual tissue-level parasites are cleared.
Its effectiveness against Plasmodium falciparum in sub-Saharan Africa remains high in most areas. Mefloquine resistance has been documented in parts of Southeast Asia.
This resistance pattern has informed decisions to prefer alternative agents in some travel regions outside Africa. For most standard East and Southern Africa safari itineraries, mefloquine remains an effective option where its side-effect profile is acceptable for the individual traveler.
Neuropsychiatric Side Effects: The Key Consideration
Mefloquine’s most significant and most discussed limitation is its association with neuropsychiatric side effects in a proportion of users. Reported effects include vivid dreams, insomnia, anxiety, depression, confusion, paranoia, and, rarely, hallucinations and psychosis.
The FDA added a black box warning to mefloquine in 2013. It noted that neurological and psychiatric side effects may persist long after the drug is discontinued in some patients.
The proportion of travelers who experience significant neuropsychiatric effects is debated. Estimates in the literature vary from below five percent to over 20 percent depending on how severity is defined and what population is studied.
Even at the lower estimates, the potential for serious psychological effects makes physician assessment of each traveler’s individual risk profile essential before mefloquine is prescribed.
Mefloquine is specifically contraindicated for travelers with a history of psychiatric illness, epilepsy, seizure disorders, or cardiac conduction abnormalities.
The five-week pre-departure course recommendation exists specifically to identify travelers who develop neuropsychiatric effects at home.
These travelers have access to medical support and can switch to an alternative prophylactic before travel. The practical implication is that mefloquine is most suitable for travelers without relevant contraindications who are planning well ahead.
The weekly dosing convenience must significantly outweigh the side-effect concern for it to be the right choice. Travelers should also discuss their specific medical and psychiatric history thoroughly with their physician before beginning the course.
Making the Right Choice
The right antimalarial choice is the one that your physician recommends based on your complete medical history, the specific malarial risk level of your destinations, the duration of your trip, and your budget.
And your tolerance for the different side-effect profiles of each option. For most short-to-medium duration East and Southern African safaris in otherwise healthy travelers, atovaquone-proguanil is the most commonly recommended option.
Its short post-travel course, favorable side-effect profile, and reliable efficacy make it the go-to choice. Doxycycline is frequently recommended for longer trips where the cost difference is significant.
Mefloquine is less commonly first-line in current UK and US clinical practice due to neuropsychiatric concerns. It remains appropriate for specific traveler profiles and itineraries where a physician judges it the best option.
Whichever prophylactic you are prescribed, the medication must be combined with insect bite avoidance measures. DEET-based repellent, covered clothing at dusk and dawn, and bed nets in open accommodation provide optimal protection.
No antimalarial medication provides 100 percent protection. The multi-layered prevention approach combining pharmaceutical and non-pharmaceutical measures significantly reduces the residual risk that any single intervention leaves.
Travelers should also be aware of malaria symptoms—fever, chills, headache, muscle pain, and fatigue. They should seek medical attention promptly if these develop during or after travel to a malarial area.
The attending physician should be informed of recent travel history and prophylaxis use.
Plan Your Safari
Malaria prophylaxis decisions require a travel clinic consultation with your complete medical history and specific itinerary to hand. African Wild Trekkers provides destination-specific malaria risk information as part of our pre-departure briefing for all clients. This includes the current risk level for each park and country on your itinerary so that your clinic appointment starts from the most accurate destination picture possible.
We also include emergency medical contact information for each destination. Including flying doctor services in East Africa and emergency medevac contacts for Southern Africa — in all pre-departure documentation. Every traveler is prepared for any health event in the bush.
Contact African Wild Trekkers at africanwildtrekkers.com/contact with your destination countries, and we will provide destination-specific health preparation guidance alongside your itinerary design within 24 hours.
